FIGURE 3.

VEGFR2 blockade enhances the antiproliferative effects of molecular targeted therapies in vitro. A, Cell proliferation assays in cells treated with the indicated concentrations of each molecular targeted agent. Ramucirumab was used at 150 μg/mL. All experiments were performed in triplicate, and representative data are shown. B, Antiproliferative effects of the combination therapy with erlotinib (100 nmol/L), alectinib (100 nmol/L), and ramucirumab (150 μg/mL) in PC‐9 and H3122 cells over 96 h, as determined by MTT assay. Data are presented as means ± SE. *P < .001